Edgar Snyder & Associates®
A Law Firm Representing Injured People
Call Us Toll Free 24/7
Published on Apr 13, 2006 by Edgar Snyder

Fosamax Next Worry for Merck


Merck’s worries may not end with Vioxx. Attorneys are drawing their attention to Merck’s osteoporosis drug Fosamax, used to treat osteoporosis, for leading to a rare jawbone disease called osteonecrosis of the jaw (ONJ). ONJ causes the jawbone to rot and die.

The lawsuits claim that Merck sold and heavily marketed the drug as safe despite knowing it lead to ONJ. Unlike with Vioxx, Merck can not get away with claiming there are a number of other factors that could have caused the disease since it is so rare.

Fosamax belongs to the bisphosphonates class of drugs that also includes Actonel and Boniva. However, attorneys have focused on Fosamax because data from the Food and Drug Administration (FDA) shows a much higher rate of ONJ with Fosamax than with other drugs.

For more information about dangerous drugs, visit our Dangerous Drug and Recall Legal Center.

Drug litigation may involve co-counsel.

Source: “Fosamax Drug Could Become Next Merck Woe.” By John Carreyrou. The Wall Street Journal. April 12, 2006.
Think you have a case?
Think you have a case?
Free Case Review
First Name
Last Name
Briefly describe your injuries

Recent News

Sep 28, 2016
Pittsburgh Police Beefing Up DUI Patrols in 2017
Sep 26, 2016
Gear Up, Cool Down, and Stay Safe While Riding This Fall
Sep 16, 2016
Fall and Winter Car Kit
Sep 16, 2016
A New Law May Be Coming for Drivers
Sep 16, 2016
Smartphone Apps for Drivers